Poor
Not Aligned
Patient Risk:
High
Summary
Several key claims are marked absent from the provided label content (notably pregnancy and pediatric age limits), and multiple administration/timing instructions are not supported. Only a subset of counseling points (photosensitivity; completing course) aligns with the label excerpt.
Category Scores
Accurate Statements
Doxycycline can cause photosensitivity, so sun exposure should be avoided.
17 PATIENT COUNSELING INFORMATION: avoid excessive sunlight or artificial ultraviolet light; discontinue if phototoxicity occurs.
Doxycycline should be taken to complete the full course unless the clinician tells otherwise.
17 PATIENT COUNSELING INFORMATION: take exactly as directed; skipping/not completing may decrease effectiveness and increase resistance.
Unsupported Statements
Doxycycline should be used only with a doctor's prescription.
No supporting statement found in the provided label excerpts.
A licensed manufacturer should have clear labeling including batch number, expiry, and a DRAP/licensed mark.
Not supported by the provided FDA label excerpts.
After taking doxycycline, the patient should not lie down for 30 minutes.
Not supported by the provided label excerpts.
Contradictions
Important Omissions
Pregnancy-related recommendations/contraindications or precautions for doxycycline hyclate delayed-release tablets.
Importance:
High
Pediatric age-related recommendations for doxycycline hyclate delayed-release tablets (e.g., guidance by age threshold).
Importance:
High
Contraindication information based on hypersensitivity to tetracyclines.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
The response asserts pregnancy and pediatric age limitations despite being unsupported by the provided label excerpts, and includes esophageal-related administration guidance (no lying down for 30 minutes) and prescriber-prescription/regulatory-mark statements that are not supported. Only limited counseling points align with the provided label content.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Priority safety/patient population claims (pregnancy and children under 8) are not supported by the provided label excerpts, and multiple administration/timing/regulatory claims are also not supported.
Suggested Improvement
Restrict claims to text supported by the provided label sections; remove unsupported items (e.g., pregnancy/pediatric age limits, 30-minute upright instruction, DRAP/licensed mark, prescription-only statement) and align interaction counseling to the label’s described absorption reductions without adding unlisted timing details ('within a couple of hours', 'full glass of water').